• Home
  • >>>>>>>>>>>>> 2026 & BEYOND MASTER PLAN >>>>>>>>>>>>>>>>
  • Virtual Data Room (VDR) for Strategic Customized Slide Decks
  • TRAINABLE DATA ASSETS IN CORPORATE LEGACY & ORGANIZATION’s STRATEGIC MEMORY (2012 – 2025)
  • 2.0 LPBI Executive Summary
  • 1.0 LPBI Executive Summary
  • Founder’s Vision
  • Portfolio of IP Assets
  • Knowledge PORTALS System (KPS)
  • 1.0 LPBI – 2012-2020 VISTA
  • LPBI Group’s History
  • 2.0 LPBI – 2021-2025 VISION
  • BioMed e-Series
  • Press Coverage
  • Investor Relations
  • Our TEAM
  • Founder’s Bio
  • Funding, Deals & Partnerships
  • 1.0 LPBI Group News
  • 1.0 LPBI CALENDAR
  • 2.0 LPBI Group News
  • Testimonials about LPBI
  • DrugDiscovery @LPBI Group
  • Medical 3D Printing
  • e-VOICES Podcasting
  • LPBI Newsletters
  • Customer Surveys
  • Health Care INVESTOR’s Corner ($)
  • 2021 Summer Internship Portal
  • 2021-2025 Medical Text Analysis (NLP)
  • Artificial Intelligence: Genomics & Cancer
  • Blockchain Transactions Network Ecosystem
  • 1.0 LPBI Brochure
  • 2.0 LPBI Brochure
  • 2.0 LPBI – Calendar of Zooms
  • Coronavirus, SARS-CoV-2 Portal
  • LPBI India
  • SOP Web STAT
  • Synthetic Biology in Drug Discovery
  • Certificate One Year
  • NFT: Redefined Format of IP Assets
  • Audio English-Spanish: BioMed e-Series
  • Five Bilingual BioMed e-Series
  • Press Releases
  • Intangibles CIM
  • BioMed Audio Podcast Library @LPBI Group
  • Medical School Education: Use of LPBI Group’s Contents
  • ChatGPT + Wolfram PlugIn
  • Medicine with GPT-4 & ChatGPT
  • AGI, generativeAI, Grok, DeepSeek & Expert Models in Healthcare
  • Multimodal Healthcare Foundation Model
  • Cell Therapy in Regenerative Medicine, 2026 and Beyond
  • Contact Us

Leaders in Pharmaceutical Business Intelligence Group, LLC, Doing Business As LPBI Group, Newton, MA

Healthcare analytics, AI solutions for biological big data, providing an AI platform for the biotech, life sciences, medical and pharmaceutical industries, as well as for related technological approaches, i.e., curation and text analysis with machine learning and other activities related to AI applications to these industries.

Feeds:
Posts
Comments

WHAT ARE LPBI Group’s NEEDS in June 2019: Aviva’s BOLD VISION on June 11, 2019

WHAT ARE LPBI Group’s NEEDS in June 2019

Aviva’s BOLD VISION on June 11, 2019

 

 

Task 1:   Artificial Intelligence in Medicine

– Weekly engagement

https://www.aiin.healthcare

 

Majority of healthcare organizations are testing out AI

June 05, 2019 | Amy Baxter | Connected Care

https://www.aiin.healthcare/topics/connected-

care/majority-healthcare-organizations-are-

testing-out-ai?utm_source=newsletter&utm_medium=cvb_news

 

Task 2:   Promotion of BioMed e-Series to Med Schools

– Monthly engagement

 

Task 3:   Going DIRECT for finding an M&A partner

– Quarterly engagement

 

Team Member Task Assignment

 

FIT Member Task 1:

AI in Medicine

https://www.aiin.healthcare

Task 2:

BioMed e-Series introduction to Med Schools

Science

Team

Weekly ONE page post on AI in Medicine Monthly milestones two schools send e-mail to Specialty Faculty Members on ONE series

July 15, 2019 report

Dr. Irina Robu Yes – AI in Pathology Series E in Canada
Dr. Sudipta Saha Yes – AI in Biological Sciences Series D

in India

Dr. Dror Nir

________

 

Dr. Justin Pearlman

Yes – AI in Medical Imaging

Ultrasound, MRI, CT, CTA

Yes – AI in Robotics-assisted Surgery

Series C 

UK

_________

Series A

MA, NH

Dr. Stephen J. Williams Yes – AI in Cancer Series B & C

PA & MD

Prof. Feldman Yes – AI Technologies and Methodologies All Series

OR

AZ

Aviva Yes – CVD All Series

MA

Business

Team

Weekly ONE page post on AI in Medicine
Gail AI in Health care Series E

NJ

Amnon AI in Biotech FIN Series E

ISRAEL

Rick AI in HealthIT Series B

UT

Aviva

 

___________

AI in Diagnostics Series A

Japan

Non-Active:

  • Dr. Larry,
  • Adam
Snooze mode

 

 

WHAT ARE LPBI Group’s NEEDS in June 2019

Aviva’s BOLD VISION on June 11, 2019 – Continued

 

 

Task 3:   Going DIRECT for finding an M&A partner

– Quarterly engagement

 

Team Member Task Assignment

 

FIT Member Task 3:

Niche Playing to find DIRECTLY M&A partner

Specials
Science

Team

Quarterly report – October 1, 2019  
Dr. Irina Robu Pharma or Education  
Dr. Sudipta Saha India Academic Publishing  
Dr. Dror Nir Big MedTech Equipment GE, Siemens, Phillips  
Dr. Stephen J. Williams One of these three:

  • Big Pharma – Top 20 R&D & Ventures
  • HealthCare Insurers – US
  • Geisinger Medical Center, Lancaster, PA

 

7/15/19 start Genomics Vol 2

November 1, Submit to Aviva

________

Prof. Feldman Australia & New Zealand potentially interested parties in the Journal, Books, eProceedings 7/15/19 start Genomics Vol 2

November 1, Submit to Aviva

________

Aviva

&

Dr. Pearlman

UK – Media

Germany – Academic Publishing

Aviva needs to Finish Genomics Vol 2

to be published in 2019

Business

Team

Quarterly report – October 1, 2019
Gail Global Media & Publishing Players Clarivate – Reuters

https://clarivate.com/

Amnon Choose three of the GLOBAL FIN to find M&A for LPBI Group IP Assets

https://pitchbook.com/news/search?media-types=AR&tags=top-investor

 

Rick Private equity in health care:

Choose three of the FIN to find M&A for LPBI Group IP Assets

 

Aviva

 

_________

Europe – focus  
Non-Active:

  • Dr. Larry
  • Adam

 

 

Share this:

  • Share on X (Opens in new window) X
  • Share on LinkedIn (Opens in new window) LinkedIn
  • Share on Facebook (Opens in new window) Facebook
  • Print (Opens in new window) Print
  • Email a link to a friend (Opens in new window) Email

Like this:

Like Loading…

  • Follow Blog via Email

    Enter your email address to follow this blog and receive notifications of new posts by email.

    Join 2,041 other subscribers
  • Recent Posts

    • In Memoriam: In Remembrance of Cancer Researchers who passed in 2026 July 13, 2026
    • Urgent Request for Action on Proposed Rule Affecting Federal Funding Grant Review July 7, 2026
    • 2026 Tang Prize in Biopharmaceutical Science Awarded to Three Pioneers of Cellular Immunotherapy Revolutionizing Treatments for Blood Cancers and Solid Tumors July 5, 2026
    • Protected: KOL on Competitive Dynamics: LPBI Group’s Founder’s Radar Screens on AI in Health, Life Sciences & BioPharma June 15, 2026
    • Tumor Infiltrating Lymphocytes (TIL) as a first of kind FDA approved immunotherapy for cancer June 12, 2026
    • A Systematic Analysis of Competitive Dynamics in the AI Revolution — Strategic Relevance to LPBI Group’s Mission – Alex Wissner-Gross Daily Newsletters by KOL (March 1 – June 10, 2026, to be extended to Present) June 11, 2026
    • In Memoriam: Professor Yitzhak Apeloig, President and Distinguised Professor of the Technion June 4, 2026
    • Top VC Investors in AI / Health AI in 2026 May 26, 2026
    • Grok thinks like PhDs – Hybrid Model for Autonomous Update of Doctoral Dissertations with Original PhD Student Author editing and acceptance of Grok’s updated output. 3rd Joint article, a pilot study for Validation of an Autonomous Journal Articles Updating System (AJAUS) tested on Autonomous Update of Aviva Lev-Ari, PhD, RN Doctoral Thesis, UC, Berkeley, 1983. January 31, 2026
    • 2026 World Economic Forum, 1/19 – 1/23/2026, Davos, Switzerland, LPBI Group’s KOLs interpretation of AI in Health Videos January 24, 2026
  • Archives

  • Categories

  • Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org
    • 1 2012pharmaceutical
    • 1 sjwilliamspa

Powered by WordPress.com.

WPThemes.


%d